BAVA Bavarian Nordic A/S

Bavarian Nordic’s Sale of Priority Review Voucher Receives Antitrust Clearance

Bavarian Nordic’s Sale of Priority Review Voucher Receives Antitrust Clearance

COPENHAGEN, Denmark, January 22, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the sale of its Priority Review Voucher (PRV) has received antitrust clearance. The transaction, which was announced on December 17, 2019 will now proceed towards closing, expected by end of January 2020.

For more information about the PRV sale, see .

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit .

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel:

Graham Morrell, Paddock Circle Advisors (US)



Tel:

Company Announcement no. 03 / 2020

Attachment

EN
22/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic KØBENHAVN, Danmark, 2. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at bestyrelsen har indgået en aftale med administrerende direktør, Paul Chaplin, som ønsker at træde tilbage af personlige årsager. Paul Chaplin vil fortsætte i sin rolle indtil udgangen af 2026 eller indtil en efterfølger er identificeret. Bestyrelsen har igangsat processen med at identificere en ny administrerende direktør. Paul Chaplin har været hos Bavarian Nordic siden 1999 og blev udnævnt til administrerende direktør i 2014....

 PRESS RELEASE

Paul Chaplin Steps Down as CEO of Bavarian Nordic

Paul Chaplin Steps Down as CEO of Bavarian Nordic COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO. Paul Chaplin has been with Bavarian Nordic since 1999 and was appointed CEO in 2014. He has led the development of the Company’s smallpox and mpox vacci...

 PRESS RELEASE

Bavarian Nordic offentliggør foreløbige resultater for 2025 og forvent...

Bavarian Nordic offentliggør foreløbige resultater for 2025 og forventninger til 2026 Resultatet overgår de seneste forventninger til 2025 efter en stærk udvikling i begge kommercielle forretningsben, Travel Health og Public Preparedness.Forventningerne til 2026 afspejler en fortsat vækst i Travel Health (10% fra egne produkter, 14% i konstant valuta) og et normaliseret år inden for Public Preparedness, begge områder i overensstemmelse med selskabets offentliggjorte vækstambitioner på mellemlang sigt. KØBENHAVN, Danmark, 12. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i ...

 PRESS RELEASE

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provide...

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026 Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.2026 guidance reflects continued growth in Travel Health (10% from own products, 14% at constant exchange rates) and a normalized year in Public Preparedness, both in line with the communicated mid-term growth ambitions. COPENHAGEN, Denmark, February 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2025 a...

 PRESS RELEASE

Bavarian Nordic – afslutning af aktietilbagekøbsprogram

Bavarian Nordic – afslutning af aktietilbagekøbsprogram KØBENHAVN, Danmark, 9. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 7. januar 2026, nu er afsluttet, da aktier til en samlet værdi af ca. DKK 150 mio. er tilbagekøbt som planlagt. Dette udgjorde den første del af et samlet planlagt aktietilbagekøb på op til DKK 500 mio. i løbet af 2026. Bavarian Nordic vil beholde de tilbagekøbte aktier som egne aktier med det formål at tilpasse kapitalstrukturen. Programmet blev gennemført i overensstemmelse med bestem...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch